News Release

Early Signs Show Possible Role Of Amyloid Related Therapies In Slowing Down Alzheimer’s

London, 22 July 2015

Updated research from clinical trials presented today at the Alzheimer's Association International Conference (AAIC) in Washington DC shows encouraging results that indicate amyloid related therapies could possibly slow down the progression of Alzheimer’s. These early findings were supported by three industry studies of alternative antibody therapies.

Professor Serge Gauthier, Chair of the Alzheimer's Disease International (ADI) Medical and Scientific Advisory Panel, commented: ‘Today’s news is encouraging and justifies the continuation of these clinical trials. If these trials demonstrate enhanced cognition, then in time we can expect a new drug coming to the market.’

Despite today’s exciting updates, ADI is advocating for more research funding in dementia. Compared to other diseases, funding for Alzheimer’s research lags behind and needs to increase 3-4 fold to 1% of the annual cost of dementia, which in 2010 was estimated to be US$604 Billion.

Alzheimer’s disease and related dementias are a global epidemic that, according to our latest research is set to treble from an estimated 44 million today to 135 million people by 2050. This makes Alzheimer’s disease one of the most significant social, health and economic crises of the 21st century.

Marc Wortmann, Executive Director of Alzheimer’s Disease International, says ‘It is important for people to get diagnosed early in the course of the illness as these therapies are most beneficial during the early stages of the disease. That is why ADI is calling on all governments to invest in early diagnosis and early intervention strategies.’

Individuals can also play an important role by making themselves available to participate in clinical trials. And, at the same time, research into care interventions needs to continue to best support people affected by dementia today.

###

Notes to editors

About Alzheimer’s Disease International

ADI is the international federation of 83 Alzheimer associations around the world, in official relations with the World Health Organization. ADI's vision is an improved quality of life for people with dementia and their families throughout the world.

ADI believes that the key to winning the fight against dementia lies in a unique combination of global solutions and local knowledge. As such, it works locally, by empowering Alzheimer associations to promote and offer care and support for people with dementia and their carers, while working globally to focus attention on dementia and campaign for policy change from governments.

For more information, visit www.alz.co.uk.